Objective and design: The study comprised three protocols. Protocol 1 compared a HPLC method with the commonly employed colorimetric diazocoupling method. Protocol 2 examined, if the last dosage of paminobenzoic acid (PABA) could be advanced in the old to allow for a delayed age-dependent urinary excretion of PABA. Protocol 3 established limits for recovery of PABA in 24 h urine applying the HPLC method. Subjects and setting: A total of 151 healthy volunteers participated in the study of which 140 were accepted. In protocol 1: 37 subjects aged 20±78 y were included. All subjects took PABA as recommended (80 mg orally at 08.00, 12.00 and 18.00 h). Protocol 2: compared urinary PABA excretion in two groups of 80 y old subjects who had their last PABA dosage administered at 15.00 h (n 16) and at 18.00 h (n 31), respectively. Protocol 3: comprised 56 subjects aged 20±80 y. In the younger age group (20±59 y; n 34) PABA was taken as recommended, whereas in the older age group (60±80 y; n 22) the last PABA dosage was advanced three hours. Results: Protocol 1: HPLC gave signi®cantly lower PABA recovery results compared to colorimetry, the difference between methods being 23.9 AE 8.5 mg/24 h (P`0.001). Protocol 2: higher PABA recoveries were demonstrated with the advanced dosage schedule compared to the recommended schedule (208 AE 14 mg/24 h vs 181 AE 22 mg/24 h; P`0.001). Protocol 3: PABA recovery with HPLC was 211 AE 12 mg/24 h, and the lower limit comprising 95% of subjects was 187 mg/24 h. Similar PABA recoveries were demonstrated in the younger subjects and the older subjects (211 AE 11 mg/24 h vs 211 AE 13 mg/24 h; NS). Conclusion: An advanced dosage schedule for PABA in the aged is recommended. Because of lower recoveries with HPLC, the low limit for recovered PABA in a complete 24 h urine differs from the limit based on colorimetry. This study found a limit of 187 mg/24 h corresponding to the lower 95% con®dence limit for a single subject.
Introduction
introduced p-aminobenzoic acid (PABA) as an objective marker to validate the completeness of 24 h urine collection, and showed that the lowest acceptable recovery for PABA administered as 80 mg tablets 3 times daily with each main meal was 205 mg when using a colorimetric method. However, some limitations of the use of PABA have been outlined (Knuiman et al, 1986; Bingham et al, 1988; Roberts et al, 1990; Leclercq et al, 1991; Bingham et al, 1992) . Some data question the analytical method used for PABA determination because the colorimetric method co-determines aromatic amines, compounds that can originate from the intake of a number of commonly used drugs, notably paracetamol and sulphonamides (Berg et al, 1985; Brown et al, 1974; Hung et al, 1987; Ito et al, 1982; Kastel et al, 1994; Ward et al, 1985) . Other data suggest that PABA recoveries are lower in the elderly compared to the young subjects, probably re¯ecting delayed renal excretion in the elderly (Leclercq, 1991) .
This study describes a speci®c HPLC method for PABA determination, compares HPLC with the colorimetric diazocoupling method for analysis of PABA in 24 h urine, and delimits recovery of PABA for completeness of 24 h urine collection. Further, the study examines if delayed PABA excretion in the elderly can be overcome by advancing the dosage schedule.
Materials and methods

Analytical methods
Liquid chromatography was performed by the following procedure: 1 ml 8 mol/L NaOH was added to 1 mL urine in a 25 mL conical¯ask. The¯ask was covered with tin foil, heated for 90 min at 121 C, and subsequently cooled. The volume of the solution was made up to 50 mL with 0.2 mol/L phosphoric acid. This solution was injected to a reversed phase column C18 (Spherisorb, 5ODS, 25 cm 6 4.6 mm, Phenomenex, Maccles®eld, UK) where the mobile phase was a mixture of acetonitril and water (6:1 v/v) containing 0.02 mol/L potassium dihydrogen phosphate. pH was adjusted to 3.5 with 10% phosphoric acid. The injection volume was 20 ml and the¯ow rate 1.25 mL/min. UV-absorption was measured at 290 nm. PABA eluted after 6±7 min. The amount of PABA was calculated by use of PABA as external standard. The HPLC-system (Waters, Milford, MA, USA) was equipped with a pump (model 6000A), autoinjector (WISP 710B), and an UV-detector (490E). Waters software Millenium 2010, version 2.1, was used for quanti®cation of the peak area.
The colorimetric method included alkaline hydrolysis followed by formation of diazonium salt with a coupling agent. The procedure was that described by Williams & Bingham (1986) ). A Shimadzu UV 160-A (Kyoto, Japan) spectrophotometer was used.
All reagents were of analytical grade. Standards of PABA, p-aminohippuric acid (PAHA) and p-acetamidobenzoic acid (PAAB) were purchased from Sigma (St. Louis, MO, USA).
Subjects and urine collection
A total of 151 subjects, all non-institutionalised volunteers, were enrolled in the study. No dietary changes were imposed, and all followed their normal daily routine while taking part in the study. For the collection of urine all subjects were given two 2 l brown bottles containing 10 mL 1 mol/L HCl for preservation, a 500 mL browǹ visiting' bottle, a funnel, a safety pin for attachment to a suitable place on the underclothing as a reminder, three 80 mg PABAcheck tablets (Laboratories for Applied Biology Ltd., London, UK; batch no BN8659), and a set of printed instructions. The subjects were asked to record the time of the start and ®nish of the collection on a form, together with the time of taking the tablets, any lost specimens and intake of medications during the urine collection period. Urine was received at the laboratory immediately after collection, volumes were estimated by weight (speci®c gravity 1 g/mL), and aliquots of 50 mL were stored at 720 C (maximum 30 d).
Protocols
Protocol 1: Comparison between HPLC and colorimetry. PABA recoveries by HPLC and colorimetry from 37 healthy subjects aged 20±80 y (17 males; 20 females) participating in a dietary intake study were studied. None received medications on a regular basis, but two subjects took paracetoml on the day of urine collection. The subjects were instructed to take 80 mg PABA three times with main meals on the day of urine collection, approximately at 08.00, 12.00 and 18.00 h (PABA18).
Protocol 2: PABA recovery in the old. For this part of the study, 51 subjects were recruited, all 80 y old (27 females; 24 males), who participated in a dietary intake study. All were free of current acute disease, terminal illness or mental impairment. Twenty-two subjects took a wide range of drugs regularly, mostly non-steroid antirheumatics (n 10), diuretics (n 6) or antihypertensives (n 4). Six subjects took paracetamol. One group (n 33) took the PABA with main meals (PABA18), another group (n 18) advanced the last PABA dosage to 15.00 h (PABA15).
Recovery of PABA in 24 h urine was analysed by HPLC.
Protocol 3: Limit for PABA recovery. Sixty-three healthy subjects aged 20±80 y (41 females; 22 males) were recruited from the staff, and relatives, of the National Food Agency of Denmark. Subjects 20±59 y old (n 37) were instructed to take the PABA in connection with their main meals, at 08.00, 12.00 and 18.00 h (PABA18). Subjects 60±80 y old (n 26) were instructed to advance the last PABA dosage to 15.00 h (PABA15).
A subgroup of 19 subjects was asked to collect 24 h urine twice, the time interval between collection days at least seven days apart, to determine within-subject variation for PABA recovery.
All 24 h urines were analysed by HPLC.
Statistical analysis
Agreement between colorimetry and HPLC was assessed according to Bland & Altman (1986) . Analysis of data also included t-test and linear regression. The data were tested for outliers by Dixon's outlier test (ISO 5725). P-values (two-sided)`0.05 were considered statistically signi®cant. To ®nd a difference of 5% (considered clinically interesting) between each of the age groups 20±59 y and 60±80 y, and in each of the 80 y old age groups, with an s.d. of 5% required 26 subjects in each group with a 0.05 and b 0.95. All values are mean AE s.d., unless otherwise speci®ed. Figure 1 shows typical chromatograms of, respectively, a standard, a 24 h urine without PABA and a urine with PABA. The concentration of PABA and the corresponding peak area was linearly related from 0.25 mg/mL to 25 mg/ mL (r 2 1.00). The ranges of concentrations of PABA in the collected urines were 1±7 mg/mL in the measuring solution. Within-run s.d. was 1.0% (n 10) and day-today s.d. was 2.4% (n 48), representing, respectively, repeatability and reproducibility. Table 1 shows recoveries of PABA and two metabolites (PAHA and PAAB) by HPLC. Recoveries of PAHAstandards were also tested with alkaline hydrolysation for para-aminobenzoic acid used as a marker J Jakobsen et al 1 h. The recoveries were between 87 and 93%, but increased to close to 100% if hydrolysation was extended to 90 min. The analysed content of PABA in PABA tablets were found to be 97.9 AE 1.8% (n 13). The quantitative limit of detection of PABA was 0.06 mg/mL in the measuring solution. The corresponding limit of detection for the total amount of PABA in the urine depended on volume. Mean limit of detection being 5 mg (range 2±15 mg).
Results
Analytical method
PABA spiked to urine (incl. preservative) kept at 25 C was stable for at least 10 d in a concentration of 200 mg/ml.
During the development of the method meta-hydroxybenzoic acid was used as internal standard. But external standard calibration was chosen because an unidenti®ed peak interfered with meta-hydroxybenzoic acid.
None of the subjects collected 24 h urine twice, with and without intake of PABA. However, based on the chromatograms no interferences appeared with PABA from the different kind of drugs the subjects had been taking. Table 2 gives a summary of all the data collected, and analytical results produced by HPLC.
Protocols
Protocol 1: The urine from two subjects who took paracetamol on the day of urine collection gave much higher 24 h PABA recoveries when analysed by colorimetry (400 mg and 610 mg, respectively) compared to HPLC (203 mg and 206 mg, respectively). One subject had for unknown reasons lower 24 h recovery by colorimetry (74 mg) than by HPLC (203 mg).
For the remaining 34 urine samples the plot of differences between methods against their mean, for the calculation of PABA in 24 h urine, shows reasonable good agreements (Figure 2 ). There does not seem to be any obvious relation between differences and the mean, but colorimetry results were signi®cantly higher than HPLC, the difference between the two methods being 23.9 AE8.5 mg/24 h (P`0.001). para-aminobenzoic acid used as a marker J Jakobsen et al PABA recoveries with HPLC in 24 h urine correlated inversely with age (r 70.4; P`0.05).
Protocol 2: Urine from four subjects had to be rejected (two were outliers, and two because of failure to ingest PABA dosages). There were no signi®cant differences between 24 h urine volumes and duration of collection in the two groups of 80 y old.
PABA recoveries in 24 h urine were signi®cantly lower in the PABA18 group than in the PABA15 group (P`0.001; Table 2 ).
Protocol 3: 24 h urines from 56 subjects were accepted. Rejected samples were from one subject who did not taken PABA, two were not able to carry out the collection, one was an outlier and three had not collected for full 24 h (13±20 h).
Mean PABA recovery was 211 AE 12 mg/24 h, and the lower limit comprising 95% of subjects was 187 mg/24 h. Similar recoveries were demonstrated when the younger age group (23±59 y) was compared to the older age group (60±80 y) (NS; Table 2 ).
In subjects (n 19) collecting 24 h urine twice, the recovery of PABA in the ®rst collection period was 208 AE 10 mg/24 h, and in the second collection period recovery was 212 AE 20 mg/24 h (NS).
In Figure 3A is shown the recoveries of PABA for subjects in protocol 1 and PABA18 subjects in protocol 2 (dosage schedule: 08.00, 12.00 and 18.00 h; n 66), and in Figure 3B the recoveries for subjects in protocol 3 and PABA15 subjects in protocol 2 (dosage schedule dependent on age: 08.00, 12.00 and 18.00 for ages 60 y and 08.00, 12.00 and 15.00 h for ages ! 60 y; n 72). The mean urinary PABA recovery in the group who had a dosage schedule dependent on age was 210 AE 12 mg/24 h with a lower 95% con®dence limit of 186 mg/24 h.
The subgroup aged 60±78 y from protocol 1 (PABA18; n 14) had urinary PABA recovery of 191 AE 26 mg/24 h, not signi®cantly different from the recovery of 181 AE 22 mg/24 h in the PABA18 subjects in protocol 2 (n 31). Likewise, no signi®cant difference was found between the two subgroups aged 20±59 y from protocol 1 and 3, who had urinary PABA recoveries of 207 AE 16 mg/ 24 h and 211 AE 11 mg/24 h, respectively.
Discussion
The colorimetric analysis gave higher PABA recoveries in 24 h urine than HPLC. The difference is probably explained by the determination of aromatic amines from other sources with colorimetry. The basal level of aromatic amines in urine was not measured speci®cally in our study, however, in other studies the mean basal excretion has varied between 13 mg/24 h and 24 mg/24 h (Bingham & Cummings, 1983; Knuiman et al, 1986) .
None of the urine samples analysed in this study produced peaks in the chromatograms which interfered with PABA though the subjects had been taken a variety of drugs on the day of urine collection including paracetamol. The presented HPLC method does not include calculation of glucuronide metabolites which have been detected para-aminobenzoic acid used as a marker J Jakobsen et al in urine after intake of PABA (Karnes et al, 1985) . The content of these metabolites may be the reason why we only recovered 88% of the orally administered PABA. In 10 healthy volunteers who took PABA for three days and who collected urine for three days, the recovery was reported to be 98.7 AE 3.7% with colorimetry (Roberts et al, 1990) . These results suggest that the alkaline hydrolysation does not convert all PABA metabolites present in the urine to PABA.
This study showed that PABA excretion was inversely associated with the age of the subject. PABA excretion in the subjects aged 80 y who received their third PABA dosage at 18.00 h (PABA18) was 14% lower than in subjects aged 20±59 y, a difference similar to that demonstrated by Leclercq et al (1991) between young healthy subjects aged 19±39 y and elderly aged 60±89 y.
By advancing the third 80 mg PABA dosage 3 h, from 18.00 to 15.00 h (PABA15) the PABA excretion increased to the level in subjects aged 20±59 y. The reason for the lower PABA recovery in the elderly is probably explained by delayed PABA excretion due to an age-dependent gradual decline in renal function (Papper, 1973) . Incomplete collections of urine have also been suspected to account for decreased PABA excretion in the elderly (Leclercq et al, 1991) . However, this explanation seems unlikely in our subjects, who had normal PABA excretions when the dosage schedule was advanced, and who demonstrated no group differences in 24 h urine volumes and no reported losses of urine. Renal function was not assessed in our study.
PABA excretion is almost complete in six hours in young subjects (Bingham & Cummings, 1983) . Excretion rates after PABA ingestion has not been determined in the elderly, but most likely some would demonstrate similar excretion rates as young subjects. Thus, advancing the last PABA dosage by 3 h might increase the risk of accepting a urine as complete, when it in fact was not collected for the full 24 h. The urines from the three subjects in our study who were rejected due to their information of inadequate collection durations would have been accepted as complete.
The between-subject variation in our study was 5.7% (n 56), a value smaller than the within-subject variation calculated to be 7.4% (n 19). Similar values are reported for within-subject variation in 8 healthy young subjects aged 24±47 y (Roberts et al, 1990) .
By dividing subjects into two age groups, 20±59 y and 60±80 y, and advancing the last dosage of PABA 3 h for the group of elderly subjects to 15.00 h instead of 18.00 h it is possible to assess a limit, for accepting 24 h urine to be completely independent of age. The recovery of PABA in 24 h urine in 56 subjects (protocol 3) was 211 AE 12 mg/ 24 h, and the lower limit comprising 95% of subjects was calculated to be 187 mg/24 h. Including the group aged 80 y who received their last PABA dosage 3 h advanced resulted only in a minor and insigni®cant change of mean PABA recovery (210 AE 12 mg/24 h; n 72) and the 95% lower con®dence limit (186 mg/24 h). The corresponding PABA recovery determined with the colorimetric method has been found to be 223 AE 9 mg/24 h in 33 healthy subjects 22±55 y old (Bingham & Cummings, 1983) . If the contribution from other aromatic amines, analysed to be 13 AE 7 mg/24 h, was deducted, the limit would be the same as determined with HPLC.
Consequently, this study demonstrates that when using the HPLC method, the lowest acceptable recovery of PABA for assessing completeness of 24 h urinary collection is 77.9% (187 mg/24 h) in a single observation when 240 mg (three times 80 mg) of PABA is taken. This limit will be met by 95% of the subjects.
The reliability of PABA used as an objective marker for the control of the completeness of 24 h urine is still based on the fact that the subjects do not extend urine collections beyond 24 h. The presented HPLC method does seem to make allowance for one commonly encountered source of error: the use of some widely used drugs, paracetamol and sulphonamides, on the day of urine collection. No interferences appeared with PABA from the different kind of drugs, including paracetamol, the subjects had been taking. Further studies are required to check the extraction procedure for the complete conversion of PABA metabolites to PABA, and to assess at which age the last PABA dosage should be advanced.
